Aditxt, Inc., a biotech company, has filed a Form 8-K with the SEC, reporting several significant corporate developments. On October 1, 2024, Aditxt announced an amendment to its merger agreement with Evofem Biosciences, Inc., which included changes to the schedule and amounts of equity investments in Evofem. The third equity investment was adjusted to $720,000 and the fourth to $2.28 million, with the third investment's date extended to October 2, 2024. Additionally, Aditxt completed a reverse stock split at a ratio of 1-for-40, effective October 1, 2024, with the company's common stock trading on a split-adjusted basis from October 2, 2024. The reverse stock split consolidated every 40 shares of issued and outstanding common stock into one share, with a proportionate adjustment to the exercise price and number...Show More

Aditxt, Inc., a biotech company, has filed a Form 8-K with the SEC, reporting several significant corporate developments. On October 1, 2024, Aditxt announced an amendment to its merger agreement with Evofem Biosciences, Inc., which included changes to the schedule and amounts of equity investments in Evofem. The third equity investment was adjusted to $720,000 and the fourth to $2.28 million, with the third investment's date extended to October 2, 2024. Additionally, Aditxt completed a reverse stock split at a ratio of 1-for-40, effective October 1, 2024, with the company's common stock trading on a split-adjusted basis from October 2, 2024. The reverse stock split consolidated every 40 shares of issued and outstanding common stock into one share, with a proportionate adjustment to the exercise price and number of shares issuable for stock options, restricted stock units, and warrants. The company's common stock continues to trade on the Nasdaq under the symbol 'ADTX' with a new CUSIP number. These corporate actions follow a series of amendments to the merger agreement and securities purchase agreements with Evofem, as detailed in previous SEC filings by Aditxt.